胃癌患者血浆纤溶酶原激活剂抑制物-1活性与肿瘤转移的关系

Plasma PAI-1 activity in gastric cancer and its relation with cancer metastasis

目的:探讨胃癌患者血浆纤溶酶原激活剂抑制物-1(plasminogen activator inhibitor-1,PAI-1)含量变化特点及临床意义。方法:采用酶联免疫吸附法分别测定30例胃癌患者术前和术后的PAI-1的含量,进行统计分析。结果:胃癌患者术后PAI-1含量较术前明显增高,术前术后差异有统计学意义(P<0.05);胃癌患者Ⅰ期与(Ⅱ、Ⅲ)期相比,术前术后血浆PAI-1值均增高,差异具有统计学意义(P<0.05)。结论:术前术后血浆PAI-1值是否明显增高,作为评估切除胃癌组织疗效的判断指标;PAI-1含量增高与胃癌的病理分型、分期、病程有密切的关系。

Objective：To investigate the change characteristics of plasma plasminogen activator inhibitor-1 （PAI-1） in the patients with gastric cancer to provide the experiment evidence for its treatment and prognosis.Methods：The enzyme-linked immunosorbent assay （ELISA） was applied to determine the plasma PAI-1 levels before and after operation in 30 patients with gastric cancer and to explore its clinical significance by statistical analysis. Results：Compared with before operation, the plasma PAI-1 level in the patients with gastric cancer was markedly increased after operation with significant difference between before and after operation （P〈0.01）. Comparing phase Ⅰ with phase Ⅱ , Ⅲ ,the plasma PAI-1 level before and after operation was increased with significant difference （P〈0.05）. Conclusion：The increase of plasma PAI-1 level in the patients with gastric cancer may be used as an indicator for judging the curative effect,which is closely related with the pathological types, classification and disease course of gastric cancer.